Home » Ciphergen Stockholders Approve SELDI Divestiture to Bio-Rad

Ciphergen Stockholders Approve SELDI Divestiture to Bio-Rad

Oct 29, 2006
NEW YORK (GenomeWeb News) — Ciphergen Biosystems’ shareholders have given the company the green light to sell its proteomics instrument business to Bio-Rad Laboratories.
 
Under the terms of the agreement, originally disclosed in August, Ciphergen will unload the hardware branch to Bio-Rad for about $20 million in cash and a $3 million equity investment.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Scan

When the Ailment You're Studying Becomes Personal

In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.

Irish Genomics Initiative Looks to Expand Into Scotland

An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.

Another Source of Data for 23andMe

In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.

This Week in PLOS

In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.

What's Popular?

In Proteomics & Protein Research

  1. Pan-Cancer Mutation Study Identifies Protein Kinases Key to Tumor Suppression

    Premium

  2. Top Down Proteomics Identifies Protein-Level Effects of KRAS Mutations in Colorectal Cancer

    Premium

  3. Advances in Mass Spec Push Single-Cell Proteomics Toward Feasibility

    Premium

  4. IsoPlexis Uses Single-Cell Platform to Assess T Cell Activity in CAR-T Cancer Therapy

    Premium

Sponsorships

Privacy Policy.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.